The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses

Immunology and Cell Biology

Volumn 92, Issue 4, 2014, Pages 377-383

  Chua, Brendon Y ^a   Olson, Matthew R ^a   Bedoui, Sammy ^a   Sekiya, Toshiki ^a   Wong, Chinn Y ^a   Turner, Stephen J ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvants; anti viral immunity; CD8 T cells; TLR2; vaccination

Indexed keywords

ALUMINUM HYDROXIDE; CD27 ANTIGEN; DIPALMITOYLGLYCERYLCYSTEINE; FREUND ADJUVANT; GAMMA INTERFERON; GRANZYME B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; LEUKOSIALIN; LIPOPEPTIDE; PADGEM PROTEIN; TOLL LIKE RECEPTOR 2 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; OVALBUMIN; S-(2,3-BIS(PALMITOYLOXY)PROPYL)CYSTEINE; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; IMMUNOGENICITY; INFLUENZA VIRUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROVOCATION TEST; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; AGONISTS; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM;

ANIMALIA; MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; IMMUNOLOGIC MEMORY; LIPOPEPTIDES; MICE, INBRED C57BL; OVALBUMIN; TOLL-LIKE RECEPTOR 2; VACCINATION;

EID: 84899441022     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.102     Document Type: Article

References (40)

1. Byun EH, Kim WS, Kim JS, Jung ID, Park YM, Kim HJ et al. Mycobacterium tuberculosis Rv057 7, a novel TLR2 agonist, induces maturation of dendritic cells and drives Th1 immune response. FASEB J 2012; 26: 2695-2711.
2. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118: 6836-6844.
3. Chandran SS, Verhoeven D, Teijaro JR, Fenton MJ, Farber DL. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J Immunol 2009; 183: 7832-7841.
4. Chua BY, Pejoski D, Turner SJ, Zeng W, Jackson DC. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J Immunol 2011; 187: 1692-1701.
5. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virusspecific memory CD8+ T cells. J Immunol 2007; 179: 2187-2194.
6. Deliyannis G Kedzierska K Lau YF Zeng W Turner SJ Jackson DC et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza Eur J Immunol 2006 36 770-778.
7. Wille-Reece U, Wu C-Y, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8 + T cell responses. J Immunol 2005; 174: 7676-7683.
8. Oh JZ, Kedl RM. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate v accine for eliciting cellular immunity. J Immunol 2010; 185: 4602-4608.
9. Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S et al. The synthetic TLR2 agonist BPPc ysMPEG leads to efficient cross-priming against coadministered and linked antigens. Eur J Immunol 2010; 40: 1272-1283.
10. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101: 15440-15445.
11. Zen g W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169: 4905-4912.
12. Nguyen C T, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011; 29: 57 31-5739.
13. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells . Eur J Immunol 2002; 32: 2356-2364.
14. Kastenmüller K, Wille-Reece U, Lindsay RWB, Trager LR, Darrah PA, Flynn BJ et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immu nization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 2011; 121: 1782-1796.
15. Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J et al. A selfadjuva nting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008; 26: 4866-4875.
16. Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R et al. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012; 7: e47492.
17. Jenkins MR, Webby R, Doher ty PC, Turner SJ. Addition of a prominent epitope affects influenza A virus-specific CD8+ T cell immunodominance hierarchies when antigen is limiting. J Immunol 2006; 177: 2917-2925.
18. Obar JJ, Khan na KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008; 28: 859-869.
19. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4: 1191-1198.
20. Hikono H, Kohlmeier JE, Takamura S, Wittmer ST, Roberts AD, Woodland DL. Activation phenotype, rather than central-or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J Exp Med 2007; 204: 1625-1636.
21. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005; 11: 748-756.
22. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A et al. Nano-particle vaccination combined with TLR-7 and-9 ligands triggers memory and effector C D8+ T-cell responses in melanoma patients. Eur J Immunol 2012; 42: 3049-3061.
23. Cottalorda A, Verschelde C, Marçais A, Tomkowiak M, Musette P, Uematsu S et al. TLR2 engagement on CD8 T cells lowe rs the thresholdfor optimal antigen-induced T cell activation. Eur J Immunol 2006; 36: 1684-1693.
24. Quigley M, Martinez J, Huang X, Yang Y. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 2009; 113: 2256-2264.
25. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008; 22: 3628-3637.
26. Kool M Fierens K Lambrecht BN Alum adjuvant: some of the tricks of the oldest adjuvant J Med Microbiol 2012 61 927-934.
27. Stills HF. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 2005; 46: 280-293.
28. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B et al. Ad juvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314: 1936-1938.
29. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J et al. Inflammation directs memory precursor and short-lived effector CD8(+ ) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27: 281-295.
30. Duramad O, Fearon KL, Chan JH, Kan zler H, Marshall JD, Coffman RL et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 2003; 102: 4487-4492.
31. Chen Y, Zhang J, Moore SA, Ballas ZK, Portanova JP, Krieg AM et al. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol 2001; 13: 1013-1020.
32. Yamazaki S, Okada K, M aruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 2011; 6: e18833.
33. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S et al. Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity. Clin C ancer Res 2013; 19: 1340-1346.
34. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and i n TLR1-and TLR2-deficient mice. Nat Med 2002; 8: 878-884.
35. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential ass ociation with staphylococcal infection. Infect Immun 2000; 68: 6398-6401.
36. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156-164.
37. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184: 923-930.
38. Wooten RM, Ma Y, Yoder RA, Brown JP, Weis JH, Zachary JF et al. Toll-like receptor is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002; 168: 348-355.
39. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol 2007; 8: 1060-1066.
40. Tannock GA, Paul JA, Barry RD. Relative immunogenicity of the cold-adapted i nfluenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 1984; 43: 457-462.